ESPR RSI Chart
Last 7 days
10.6%
Last 30 days
-14.9%
Last 90 days
-3.0%
Trailing 12 Months
47.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 81.0M | 87.9M | 102.9M | 116.3M |
2022 | 89.3M | 67.5M | 72.1M | 75.5M |
2021 | 233.7M | 62.1M | 72.7M | 78.4M |
2020 | 168.2M | 188.0M | 207.8M | 227.5M |
2019 | 0 | 0 | 0 | 148.4M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 14, 2024 | warren eric | acquired | - | - | 100,000 | chief commercial officer |
Mar 14, 2024 | foody joanne m. | acquired | - | - | 150,000 | chief medical officer |
Mar 14, 2024 | halladay benjamin | acquired | - | - | 170,000 | chief financial officer |
Mar 14, 2024 | koenig sheldon l. | acquired | - | - | 454,000 | president and ceo |
Mar 14, 2024 | looker benjamin | acquired | - | - | 100,000 | general counsel |
Sep 20, 2023 | warren eric | sold | -923 | 1.245 | -742 | chief commercial officer |
Aug 18, 2023 | warren eric | sold | -343 | 1.414 | -243 | chief commercial officer |
Jul 19, 2023 | warren eric | sold | -168 | 1.585 | -106 | chief commercial officer |
Jun 21, 2023 | warren eric | sold | -894 | 1.483 | -603 | chief commercial officer |
Jun 15, 2023 | fischer seth h. z. | acquired | - | - | 5,150 | - |
Which funds bought or sold ESPR recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 11, 2024 | VANGUARD GROUP INC | added | 8.36 | 10,715,300 | 15,361,900 | -% |
Mar 08, 2024 | TRUST CO OF VERMONT | sold off | -100 | -294 | - | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 79.68 | 5,169,800 | 6,323,260 | -% |
Feb 26, 2024 | Virtu Financial LLC | sold off | -100 | -178,000 | - | -% |
Feb 23, 2024 | Chicago Partners Investment Group LLC | reduced | -48.93 | 7,120 | 30,584 | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | unchanged | - | 71,000 | 106,000 | -% |
Feb 16, 2024 | HARBOUR INVESTMENTS, INC. | sold off | -100 | -7.00 | - | -% |
Feb 16, 2024 | O'Dell Group, LLC | new | - | 13,455 | 13,455 | -% |
Feb 16, 2024 | GSA CAPITAL PARTNERS LLP | added | 1.03 | 2,279,000 | 3,373,000 | 0.28% |
Feb 15, 2024 | BARCLAYS PLC | added | 36.07 | 275,000 | 362,000 | -% |
Unveiling Esperion Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Esperion Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 380.6B | 85.2B | 10.83 | 4.47 | ||||
MRK | 333.8B | 60.1B | 914.53 | 5.55 | ||||
PFE | 156.9B | 46.5B | -113.02 | 3.37 | ||||
AMGN | 153.4B | 28.2B | 22.84 | 5.44 | ||||
GILD | 91.0B | 27.1B | 16.06 | 3.35 | ||||
TEVA | 16.2B | 15.8B | -28.08 | 1.02 | ||||
MID-CAP | ||||||||
ALKS | 4.6B | 1.7B | 12.8 | 2.74 | ||||
PRGO | 4.3B | 4.7B | -335.7 | 0.92 | ||||
BHC | 3.8B | 8.8B | -6.47 | 0.44 | ||||
AMPH | 2.1B | 644.4M | 15.22 | 3.25 | ||||
SMALL-CAP | ||||||||
TLRY | 1.8B | 700.5M | -1.29 | 2.63 | ||||
TXMD | 24.2M | 70.0M | 0.35 | 0.34 | ||||
ACRX | 18.7M | - | -1.01 | 0.22 | ||||
ACOR | 14.8M | 111.1M | -0.93 | 0.13 | ||||
AGRX | 929.3K | 20.0M | -0.07 | 0.05 |
Esperion Therapeutics Inc News
Income Statement (Quarterly) | |||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -5.1% | 32.00 | 34.00 | 26.00 | 24.00 | 19.00 | 19.00 | 19.00 | 19.00 | 15.00 | 14.00 | 41.00 | 8.00 | 10.00 | 4.00 | 212 | 107 | 1.00 | 1.00 | 1.00 | 145 |
Operating Expenses | 21.3% | 75.00 | 62.00 | 63.00 | 73.00 | 61.00 | 61.00 | 71.00 | 62.00 | 71.00 | 70.00 | 73.00 | 91.00 | 105 | 84.00 | 83.00 | 76.00 | 60.00 | 67.00 | 56.00 | 58.00 |
S&GA Expenses | 36.7% | 45.00 | 33.00 | 34.00 | 30.00 | 24.00 | 25.00 | 30.00 | 30.00 | 38.00 | 39.00 | 46.00 | 61.00 | 62.00 | 49.00 | 48.00 | 42.00 | 22.00 | 18.00 | 13.00 | 12.00 |
Interest Expenses | 0.4% | 15.00 | 15.00 | 15.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 13.00 | 14.00 | 11.00 | 8.00 | 9.00 | 5.00 | 5.00 | 4.00 | 4.00 | 4.00 | - | - |
Net Income | -36.6% | -56.34 | -41.25 | -49.93 | -61.72 | -55.49 | -55.12 | -66.32 | -56.73 | -65.12 | -69.39 | -43.67 | -90.93 | -104 | -85.44 | 125 | -78.25 | -61.95 | -68.38 | -54.22 | 87.00 |
Net Income Margin | 11.2% | -1.80* | -2.03* | -2.53* | -2.95* | -3.10* | -3.38* | -3.82* | -2.63* | -3.43* | -4.24* | -5.23* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -91.8% | -37.06 | -19.32 | -24.75 | -54.36 | -42.47 | -42.83 | -50.53 | -38.99 | -57.71 | -69.17 | -47.87 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -7.0% | 206 | 221 | 235 | 252 | 248 | 313 | 304 | 343 | 382 | 225 | 280 | 279 | 353 | 251 | 330 | 180 | 214 | 255 | 309 | 236 | 143 |
Current Assets | -7.9% | 201 | 218 | 232 | 251 | 247 | 262 | 252 | 291 | 329 | 171 | 275 | 273 | 346 | 243 | 321 | 173 | 212 | 253 | 307 | 235 | 143 |
Cash Equivalents | -28.4% | 82.00 | 115 | 138 | 145 | 125 | 159 | 123 | 150 | 259 | 104 | 219 | 218 | 305 | 216 | 298 | 149 | 167 | 212 | 274 | 175 | 37.00 |
Inventory | 27.6% | 66.00 | 51.00 | 46.00 | 39.00 | 35.00 | 30.00 | 29.00 | 36.00 | 34.00 | 34.00 | 24.00 | 20.00 | 16.00 | 9.00 | 8.00 | 2.00 | - | - | - | - | - |
Net PPE | -100.0% | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 1.00 |
Liabilities | 4.7% | 661 | 631 | 607 | 581 | 572 | 607 | 596 | 592 | 579 | 588 | 585 | 548 | 449 | 242 | 245 | 230 | 194 | 187 | 179 | 61.00 | 64.00 |
Current Liabilities | 13.4% | 156 | 138 | 107 | 95.00 | 92.00 | 82.00 | 82.00 | 79.00 | 73.00 | 78.00 | 83.00 | 98.00 | 94.00 | 76.00 | 84.00 | 73.00 | 66.00 | 58.00 | 54.00 | 60.00 | 64.00 |
Shareholder's Equity | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.00 | 85.00 | - | 20.00 | 69.00 | 129 | 175 | 79.00 |
Retained Earnings | -3.8% | -1,549 | -1,492 | -1,451 | -1,401 | -1,340 | -1,284 | -1,229 | -1,163 | -1,106 | -1,041 | -971 | -928 | -838 | -734 | -648 | -773 | -695 | -633 | -564 | -510 | -598 |
Additional Paid-In Capital | 1.0% | 1,149 | 1,138 | 1,135 | 1,127 | 1,071 | 1,045 | 993 | 969 | 964 | 734 | 723 | 714 | 798 | 743 | 734 | 723 | 715 | 702 | 694 | 686 | 678 |
Shares Outstanding | 3.1% | 103 | 100 | 94.00 | 78.00 | 66.00 | 64.00 | 63.00 | 61.00 | 29.00 | 26.00 | 26.00 | - | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 143 | - | - | - | 422 | - | - | - | 593 | - | - | - | 1,410 | - | - | - | 1,090 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -91.8% | -37,056 | -19,325 | -24,750 | -54,356 | -42,472 | -42,833 | -50,532 | -38,990 | -57,706 | -69,169 | -47,866 | -89,068 | -68,550 | -86,671 | 139,391 | -69,347 | -49,994 | -58,029 | -54,009 | 91,691 | -28,692 |
Share Based Compensation | -1.8% | 2,920 | 2,975 | 3,160 | 2,903 | 3,715 | 3,537 | 3,527 | 4,436 | 4,474 | 5,497 | 8,584 | 5,751 | 6,673 | 7,264 | 7,395 | 7,053 | 6,358 | 6,327 | 6,563 | 6,636 | 6,829 |
Cashflow From Investing | - | - | - | 17,500 | 25,000 | -11,794 | 33,000 | 5,000 | -18,102 | -50,484 | - | - | - | -12,676 | 2,333 | 5,110 | 26,589 | -2,868 | -5,313 | 26,716 | 45,696 | 38,568 |
Cashflow From Financing | 203.7% | 4,471 | -4,312 | 809 | 49,492 | -30,358 | 46,292 | 18,108 | -1,436 | 213,410 | 3,655 | 49,113 | 2,045 | 170,440 | 1,597 | 3,674 | 26,014 | 7,014 | 976 | 126,536 | 1,669 | 342 |
Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenues: | ||
Total Revenues | $ 116,334 | $ 75,475 |
Operating expenses: | ||
Cost of goods sold | 43,267 | 26,967 |
Research and development | 86,107 | 118,927 |
Selling, general and administrative | 142,523 | 109,082 |
Total operating expenses | 271,897 | 254,976 |
Loss from operations | (155,563) | (179,501) |
Interest expense | (58,976) | (56,810) |
Other income, net | 5,291 | 2,652 |
Net loss | $ (209,248) | $ (233,659) |
Net loss per common share - basic (in dollars per share) | $ (2.03) | $ (3.52) |
Net loss per common share - diluted (in dollars per share) | $ (2.03) | $ (3.52) |
Weighted-average shares outstanding - basic (in shares) | 103,106,616 | 66,407,242 |
Weighted-average shares outstanding - diluted (in shares) | 103,106,616 | 66,407,242 |
Other comprehensive (loss) gain: | ||
Unrealized gain on investments | $ 2 | $ 29 |
Total comprehensive loss | (209,246) | (233,630) |
Product | ||
Revenues: | ||
Total Revenues | 78,335 | 55,863 |
Collaboration Revenue | ||
Revenues: | ||
Total Revenues | $ 37,999 | $ 19,612 |
Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 82,248 | $ 124,775 |
Short-term investments | 0 | 42,086 |
Accounts receivable | 48,494 | 33,729 |
Inventories, net | 65,623 | 35,201 |
Prepaid clinical development costs | 193 | 1,026 |
Other prepaid and current assets | 4,507 | 9,866 |
Total current assets | 201,065 | 246,683 |
Noncurrent assets: | ||
Property and equipment, net | 0 | 164 |
Right of use operating lease assets | 4,675 | 1,036 |
Intangible assets | 56 | 56 |
Total assets | 205,796 | 247,939 |
Current liabilities: | ||
Accounts payable | 31,718 | 23,040 |
Accrued clinical development costs | 3,441 | 5,426 |
Accrued legal fees | 34,284 | 21,987 |
Other accrued liabilities | 24,998 | 13,204 |
Revenue interest liability | 34,828 | 24,760 |
Deferred revenue from collaborations | 25,402 | 3,507 |
Operating lease liabilities | 1,553 | 384 |
Total current liabilities | 156,224 | 92,308 |
Convertible notes, net of issuance costs | 261,596 | 259,899 |
Revenue interest liability | 239,950 | 218,845 |
Operating lease liabilities | 3,020 | 665 |
Total liabilities | 660,790 | 571,717 |
Commitments and contingencies (Note 5) | ||
Stockholders’ (deficit) equity: | ||
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of December 31, 2023 and December 31, 2022 | 0 | 0 |
Common stock, $0.001 par value; 480,000,000 shares authorized as of December 31, 2023 and 240,000,000 shares authorized as of December 31, 2022; 120,204,513 shares issued at December 31, 2023 and 76,564,396 shares issued at December 31, 2022 | 118 | 75 |
Additional paid-in capital | 1,149,170 | 1,071,183 |
Treasury stock, at cost; 1,994,198 shares at December 31, 2023 and December 31, 2022 | (54,998) | (54,998) |
Accumulated other comprehensive loss | 0 | (2) |
Accumulated deficit | (1,549,284) | (1,340,036) |
Total stockholders' deficit | (454,994) | (323,778) |
Total liabilities and stockholders' deficit | $ 205,796 | $ 247,939 |